Table 2.
Associations between vitamin D status and clinical and therapeutic characteristics (univariate analysis) – only associated factors with a p value < 0.20 are shown in this table
| |
|
All patients |
Severe 25-(OH) vitamin D3 deficiency (<10ng/ml) |
Moderate 25-(OH) vitamin D3 deficiency (10–30 ng/ml) |
25-(OH) Vitamin D3 >30 ng/ml |
p value |
|---|---|---|---|---|---|---|
| N = 263 | N = 95 (36%) | N = 135 (51%) | N = 33 (13%) | |||
| Sex |
M, n (%) |
188 (72%) |
75 (79%) |
89 (66%) |
24 (69%) |
0.10 |
| |
F, n (%) |
75 (28%) |
20 (21%) |
46 (34%) |
9 (31%) |
|
| Age (years) mean +/− SD |
48 +/− 10 |
49 +/−9 |
46 +/−10 |
51 +/−12 |
0.03 |
|
| Ethnicity |
non-African origin, n (%) |
230 (87%) |
87 (92%) |
112 (83%) |
31 (94%) |
0.07 |
| |
African origin, n (%) |
33 (13%) |
8 (8%) |
23 (17%) |
2 (6%) |
|
| Past history of falls, n (%) |
120 (46%) |
53 (57%) |
55 (41%) |
12 (36%) |
0.03 |
|
| Co-infections |
Positive HBs antigenemia |
14 (5.3%) |
8 (8%) |
6 (4%) |
0 (0%) |
0.14 |
| |
Positive HCV serology, n (%) |
57 (22%) |
33 (35%) |
18 (14%) |
6 (18%) |
0.12 |
| Past smokers, n (%) |
52 (20%) |
20 (21%) |
25 (19%) |
7 (21%) |
0.003 |
|
| Active smokers, n (%) |
120 (46%) |
55 (59%) |
50 (37%) |
14 (45%) |
0.003 |
|
| Sun exposure (min),mean +/− SD |
106 +/− 114 |
93 +/− 108 |
102 +/− 111 |
157 +/− 132 |
0.02 |
|
| Length of HIV infection (yrs), mean +/−SD |
13 +/− 8 |
16 +/−8 |
12 +/−7 |
12 +/−8 |
0.0008 |
|
| NRTI exposure (months), mean +/− SD |
95 +/− 71 |
108 +/−70 |
89 +/−69 |
84 +/−73 |
0.08 |
|
| Lipodystrophy, n (%) |
65 (25%) |
29 (31%) |
31 (23%) |
5 (15%) |
0.005 |
|
| Karnofsky’s Index (%), mean +/− SD | 92 +/− 14 | 89 +/−17 | 92 +/−17 | 97+/−7 | 0.008 | |
M: male, F: female, NRTI: nucleoside reverse transciptase inhibitor, HBV: hepatitis B infection, HCV: hepatitis C infection.